相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Lapatinib and Gemcitabine for Metastatic Pancreatic Cancer A Phase II Study
Howard Safran et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2011)
Which Parameters to Choose for Prediction of Non-Sentinel Lymph Node Positivity in Melanoma?
Imke Satzger et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
In vitro and in vivo evidence that a combination of lapatinib plus S-1 is a promising treatment for pancreatic cancer
Masahiro Komoto et al.
CANCER SCIENCE (2010)
Phase III Randomized Comparison of Gemcitabine Versus Gemcitabine Plus Capecitabine in Patients With Advanced Pancreatic Cancer
David Cunningham et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Activity of lapatinib a novel HER2 and EGFR dual kinase inhibitor in human endometrial cancer cells
G. E. Konecny et al.
BRITISH JOURNAL OF CANCER (2008)
Delivery of PTEN via a novel gene microcapsule sensitizes prostate cancer cells to irradiation
Atsushi Tomioka et al.
MOLECULAR CANCER THERAPEUTICS (2008)
被撤回的出版物: Down-regulation of platelet-derived growth factor-D inhibits cell growth and angiogenesis through inactivation of notch-1 and nuclear factorκB signaling (Retracted article. See vol. 78, pg. 5469, 2018)
Zhiwei Wang et al.
CANCER RESEARCH (2007)
Erlotinib in pancreatic cancer patients: Do we need more information from the NCICCTG trial? - In reply
Keyue Ding
JOURNAL OF CLINICAL ONCOLOGY (2007)
Sensitivity of breast cancer cells to erlotinib depends on cyclin-dependent kinase 2 activity
Fumiyuki Yamasaki et al.
MOLECULAR CANCER THERAPEUTICS (2007)
Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer:: A randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group
Richard Herrmann et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada clinical trials group
Malcolm J. Moore et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Impact of epidermal growth factor receptor (EGFR) kinase mutations, EGFR gene amplilications, and KRAS mutations on survival of pancreatic adenocarcinoma
Jeeyun Lee et al.
CANCER (2007)
Cancer statistics, 2007
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2007)
Inactivation of Akt by the epidermal growth factor receptor inhibitor erlotinib is mediated by HER-3 in pancreatic and colorectal tumor cell lines and contributes to erlotinib sensitivity
Elizabeth Buck et al.
MOLECULAR CANCER THERAPEUTICS (2006)
KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer
A Lièvre et al.
CANCER RESEARCH (2006)
Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells
GE Konecny et al.
CANCER RESEARCH (2006)
Epidermal growth factor receptor expression in pancreatic carcinoma using tissue microarray technique
Mark Bloomston et al.
DIGESTIVE SURGERY (2006)
Molecular prognostic markers in pancreatic cancer: A systematic review
G Garcea et al.
EUROPEAN JOURNAL OF CANCER (2005)
Quantitative determination of nuclear and cytoplasmic epidermal growth factor receptor expression in oropharyngeal squamous cell cancer by using automated quantitative analysis
A Psyrri et al.
CLINICAL CANCER RESEARCH (2005)
Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas
HA Burris et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer:: Results of a GERCOR and GISCAD phase III trial
C Louvet et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib
W Pao et al.
PLOS MEDICINE (2005)
HER-2 receptor expression, localization, and activation in colorectal cancer cell lines and human tumors
E Half et al.
INTERNATIONAL JOURNAL OF CANCER (2004)
Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate
CMR Lima et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
The correlation between cytoplasmic overexpression of epidermal growth factor receptor and tumor aggressiveness - Poor prognosis in patients with pancreatic ductal adenocarcinoma
S Ueda et al.
PANCREAS (2004)
Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297
JD Berlin et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Overexpression of the HER-2/neu oncogene in pancreatic adenocarcinoma
H Safran et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2001)
Nuclear localization of EGF receptor and its potential new role as a transcription factor
SY Lin et al.
NATURE CELL BIOLOGY (2001)
Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: Results of a randomized phase II study
E Van Cutsem et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
分享论文
